RU2456002C1 - Diuretic - Google Patents

Abstract

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to experimental medicine, namely to pharmacology. The object in view is achieved by the fact that 0.5% humic acids additionally containing magnesium sulphate (II) are applied as a diuretic in the following proportions: 0.5% humic acids - 40 ml; magnesium sulphate - 0.1 g.

EFFECT: higher clinical effectiveness and eliminated side effects.

1 cl, 1 ex

Description

The invention relates to the field of experimental medicine, namely to pharmacology, preclinical studies (on small laboratory animals).

Known diuretic "Furosemide" [1].

The disadvantage of this drug is that even with a single administration, it causes a significant loss of potassium by the body, leading to the development of hypokalemia as a serious side effect. In addition, Furosemide causes an increase in blood glucose levels.

The diuretic Hypothiazide is also known [2].

The disadvantage of this tool is that when it is taken again, it causes a significant loss of potassium by the body, as a result of which the concentration of potassium in the blood decreases, the function of all vital organs suffers. In addition, Hypothiazide is available in only one dosage form - in the form of tablets for oral administration.

Also known is the drug "Humisol" [3], which is a 0.01% solution of the fractions of humic acids of the Haapsalu marine therapeutic mud in an isotonic sodium chloride solution.

The disadvantage of this drug is the low concentration of the active substance (0.01%). Thus, with the introduction of the drug "Humisol" in a dose equivalent to the claimed drug (5 mg / kg), it is required to inject subcutaneously simultaneously with 10 ml of the drug. It is impossible to inject such a large volume of the drug subcutaneously, extremely painfully and non-physiologically due to mechanical damage to the underlying tissues. In addition, at the injection site of the Gumizol preparation, the formation of an infiltrate is possible (side effect).

The aim of the invention is to increase the effectiveness of therapeutic effects and the elimination of side effects.

This goal is achieved in that a 0.5% solution of humic acids, which additionally contains magnesium sulfate (II), is used as a diuretic in the following ratio of components: 0.5% solution of humic acids - 40 ml; magnesium sulfate - 0.1 g.

A diuretic is prepared as follows: 0.1 g of magnesium sulfate is taken and dissolved in 40 ml of a 0.5% solution of humic acids at room temperature. The finished solution is sterilized with ultraviolet rays for 30 minutes, after which it is packaged in dark glass bottles with a capacity of 40 ml.

The diuretic is used as follows: administered subcutaneously (intramuscularly) at a dose of 5 mg / kg (0.5 ml / 100 g of animal weight) 1 time per day for 7-14 days.

Contraindications to taking the drug is the individual intolerance of its individual components.

The drug belongs to the list D (low-toxic substances) and is stored at a temperature of +5 to + 10 ° С.

The drug is available in dark glass bottles of 40 ml.

Preclinical example (data from experimental studies).

When conducting chronic experiments on white outbred laboratory rats of both sexes, it was found that subcutaneous administration of humic acids at a dose of 5 mg / kg of animal weight affects the excretory function of the kidneys, increasing the excretion of water by the kidneys in experimental animals by 1.42 times compared with the control ( p <0.05), sodium 1.39 times (p <0.05), creatinine - 1.43 times (p <0.05), reducing the excretion of potassium by the kidneys by 1.58 times in comparison with the control ( potassium-sparing effect) for 24 hours of the experiment. Note: hereinafter p <0.05 reliable data, p> 0.05 false data.

In chronic experiments on white outbred laboratory rats of both sexes, it was found that magnesium sulfate at a dose of 5 mg / kg of an animal’s weight affects water-salt metabolism in the following way: it reduces water excretion by kidneys in experimental animals by 1.25 times (compared to control ones) ( p> 0.05), potassium 1.30 times (p> 0.05) and creatinine 1.21 times (p> 0.05), sodium excretion does not change after 24 hours of the experiment.

In chronic experiments on white outbred laboratory rats of both sexes, it was found that the claimed diuretic at a dose of 5 mg / kg of the animal’s weight causes pronounced changes in the excretory function of the kidneys, increasing the excretion of water by the kidneys in experimental animals by 1.79 times compared with the control (p <0.05), sodium 1.81 times (p <0.05), creatinine - 2.18 times (p <0.05), reducing the excretion of potassium by the kidneys 1.76 times in comparison with the control (has pronounced potassium-sparing effect) for 24 hours of the experiment.

The use of the inventive diuretic can improve the treatment of nephropathy of various origins, including acute toxic renal failure.

A diuretic can and should be used in experimental medicine, namely pharmacology, when conducting complex therapy of experimental acute toxic nephropathy.

The claimed diuretic affects water-salt metabolism, increasing the excretion of water, sodium and creatinine by the kidneys, retaining potassium in the body, thus normalizing the excretory function of the kidneys.

Information sources

1. Mashkovsky, M.D. Medicines In two volumes. T.1. - 14th ed., Rev., Rev. and add. - M .: New Wave Publishing House LLC, Publisher S.B. Divov, 2002 .-- 540 s., 8 s. silt.

2. The register of medicines of Russia. Encyclopedia of drugs. 10th issue. - M .: radar - 2003, 2003 - 1440 s.

3. Mashkovsky, M.D. Medicines In two parts. Part II. - 12th ed., Revised. and add. - M.: Medicine, 1993 .-- 688 p.

Claims (1)

A diuretic containing a 0.5% solution of humic acids and magnesium sulfate (II) in the following ratio of components:
0.5% humic acid solution 40 ml magnesium sulfate 0.1 g